May 13, 2026 10:10 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Vijay-led TVK wins Tamil Nadu floor test as AIADMK split plays out | Congress veteran Sonia Gandhi admitted to Medanta Hospital in Gurugram | PM Modi halves convoy size after austerity call | Mulayam Singh's younger son Prateek Yadav dies at 38 | Protests erupt in Delhi after NEET UG 2026 cancellation over alleged paper leak | AIADMK cracks widen after Tamil Nadu defeat; faction backs Vijay-led TVK government | Himanta Biswa Sarma takes oath as Assam CM for second term after BJP’s landslide win | Bengali rights activist Garga Chatterjee arrested over alleged provocative remarks ahead of assembly polls | No return to full WFH yet: IT firms unlikely to change hybrid work model despite PM Modi’s appeal | Suvendu Adhikari Cabinet clears BSF land transfer, census rollout, Ayushman Bharat in Bengal
Covid-19 | DRDO
Image Credit: PIB

DRDO arm develops COVID-19 antibody detection kit DIPCOVAN

| @indiablooms | May 22, 2021, at 05:50 am

New Delhi/IBNS: The Defence Institute of Physiology and Allied Sciences (DIPAS), a unit under the Defence Research and Development Organisation (DRDO) has developed an antibody detection-based kit “DIPCOVAN", for sero-surveillance, a statement from DRDO said Friday.

The DIPCOVAN kit can detect both spike as well as nucleocapsid (S&N) proteins of SARS-CoV-2 virus with a high sensitivity of 97 per cent and specificity of 99 per cent.

The kit has been developed in association with Vanguard Diagnostics Pvt Ltd, a development and manufacturing diagnostics company based at New Delhi.

The DIPCOVAN kit was developed indigenously by the scientists, followed by extensive validation on more than 1,000 patient samples at various COVID designated hospitals in Delhi, the statement said.

Three batches of the product were validated during last one year.

The antibody detection kit is approved by Indian Council of Medical Research (ICMR) in April 2021.

In May 2021, the product received the regulatory approval from the Drugs Controller General of India (DCGI), Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare, to manufacture for sale and distribution.

DIPCOVAN is intended for the qualitative detection of IgG antibodies in human serum or plasma, targeting SARS-CoV-2 related antigens.

"It offers a significantly faster turn-around-time as it requires just 75 minutes to conduct the test without any cross reactivity with other diseases. The kit has a shelf life of 18 months," the statement said.

Industry partner Vanguard Diagnostics Pvt. Ltd will commercially launch the product during the first week of June 2021.

Readily available stock at the time of launch will be 100 kits (approx. 10,000 tests) with a production capacity of 500 kits/month after the launch. It is expected to be available at about Rs 75 per test.

The kit will be very useful for understanding COVID‐19 epidemiology and assessing an individual's previous SARS‐CoV‐2 exposure.

Raksha Mantri Shri Rajnath Singh has appreciated the efforts of DRDO and the industry in developing the kit at the time of need.

Secretary Department of Defence R&D & Chairman DRDO Dr G Satheesh Reddy complimented the teams involved in developing the kit and said the initiative will help the people during the pandemic.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.